PRIMARY STUDY
Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease
Key Findings: In normotensive subjects with autosomal dominant polycystic kidney disease (ADPKD) candesartan cilexetil effectively reduced levels of urinary liver-type fatty acid-binding protein (L-FABP) which has previously been linked to poorer prognosis when elevated.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 40
Study Result: Positive
Research Location(s): Japan
Year of Pub: 2005
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Citation: Nakamura T, et al. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. Am J Med Sci. 2005; 330:161-5. doi: 10.1097/00000441-200510000-00002
Authors: Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H
